EP2049105A4 - Antimikrobielle photodynamische therapie - Google Patents

Antimikrobielle photodynamische therapie Download PDF

Info

Publication number
EP2049105A4
EP2049105A4 EP07797049.9A EP07797049A EP2049105A4 EP 2049105 A4 EP2049105 A4 EP 2049105A4 EP 07797049 A EP07797049 A EP 07797049A EP 2049105 A4 EP2049105 A4 EP 2049105A4
Authority
EP
European Patent Office
Prior art keywords
photodynamic therapy
antimicrobial photodynamic
antimicrobial
therapy
photodynamic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07797049.9A
Other languages
English (en)
French (fr)
Other versions
EP2049105A2 (de
Inventor
Nikolay E. Nifantiev
Burkhard Gitter
Dmitri V. Yashunsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec AG
Original Assignee
Biolitec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/880,974 external-priority patent/US20090030257A1/en
Application filed by Biolitec AG filed Critical Biolitec AG
Publication of EP2049105A2 publication Critical patent/EP2049105A2/de
Publication of EP2049105A4 publication Critical patent/EP2049105A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
EP07797049.9A 2006-07-27 2007-07-27 Antimikrobielle photodynamische therapie Withdrawn EP2049105A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83383606P 2006-07-27 2006-07-27
US11/880,974 US20090030257A1 (en) 2007-07-25 2007-07-25 Anti-microbial photodynamic therapy
PCT/US2007/016951 WO2009014524A2 (en) 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy

Publications (2)

Publication Number Publication Date
EP2049105A2 EP2049105A2 (de) 2009-04-22
EP2049105A4 true EP2049105A4 (de) 2022-03-30

Family

ID=40282008

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07797049.9A Withdrawn EP2049105A4 (de) 2006-07-27 2007-07-27 Antimikrobielle photodynamische therapie

Country Status (4)

Country Link
EP (1) EP2049105A4 (de)
BR (1) BRPI0714667A8 (de)
MX (1) MX2009001074A (de)
WO (1) WO2009014524A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220061106A (ko) 2019-08-02 2022-05-12 코이트 헬스 오와이 전신적으로 적용하는 항생제의 항균 작용을 강화하는 방법
CN114053406B (zh) * 2021-11-23 2022-12-09 华中科技大学 一种多功能光热纳米杀菌材料及制备与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462070B1 (en) * 1997-03-06 2002-10-08 The General Hospital Corporation Photosensitizer conjugates for pathogen targeting
US20040186087A1 (en) * 2003-03-20 2004-09-23 Ceramoptec Industries, Inc. Siderophore conjugates of photoactive dyes for photodynamic therapy
US20050281777A1 (en) * 2004-06-18 2005-12-22 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
EP1610751A4 (de) * 2001-04-26 2006-05-24 Univ Texas Therapeutisches mittel/ligand-konjugat-zusammensetzungen, ihre syntheseverfahren und ihre anwendung
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
AU2005204428A1 (en) * 2004-01-07 2005-07-28 Ambit Biosciences Corporation Conjugated small molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462070B1 (en) * 1997-03-06 2002-10-08 The General Hospital Corporation Photosensitizer conjugates for pathogen targeting
US20040186087A1 (en) * 2003-03-20 2004-09-23 Ceramoptec Industries, Inc. Siderophore conjugates of photoactive dyes for photodynamic therapy
US20050281777A1 (en) * 2004-06-18 2005-12-22 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes

Also Published As

Publication number Publication date
EP2049105A2 (de) 2009-04-22
WO2009014524A3 (en) 2020-10-15
BRPI0714667A2 (pt) 2013-08-06
BRPI0714667A8 (pt) 2016-10-18
WO2009014524A2 (en) 2009-01-29
MX2009001074A (es) 2009-06-05

Similar Documents

Publication Publication Date Title
CY2018004I1 (el) Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης
ATE525088T1 (de) Kombinationstherapie
EP2077901A4 (de) Okulare radiochirurgie
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
DK2054030T3 (da) Antimikrobielle midler
DK2035369T3 (da) Terapeutiske
BRPI0916931A2 (pt) agentes terapêuticos
DK2144905T3 (da) Terapeutiske midler
DE602006004866D1 (de) Katheter
BRPI0720347A2 (pt) dispositivo implantável
PT2115472E (pt) Biomarcadores de cancro
IL196559A0 (en) Combination therapy
EP2190371A4 (de) Antimikrobielles implantat
DK2219683T3 (da) Målrettet radioterapi
DK1993589T3 (da) Behandlinger for neurologiske sygdomme
IL196556A0 (en) Combination therapy
DK2173831T3 (da) Brøndbehandling
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
EP2054061A4 (de) Kombinationstherapie
BRPI0920743A2 (pt) ribonucleases terapeuticas
BRPI0810384A2 (pt) Terapia enzimática anticâncer
BRPI0818598A2 (pt) agentes terapêuticos - 802
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
HUE038563T2 (hu) Rák kezelési eljárás
DE502006006067D1 (de) Ng

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOLITEC PHARMA IP & INVESTMENT LTD.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG

R17D Deferred search report published (corrected)

Effective date: 20201015

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210415

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031407000

Ipc: A61K0041000000

A4 Supplementary search report drawn up and despatched

Effective date: 20220225

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/04 20060101ALI20220221BHEP

Ipc: A61K 31/407 20060101ALI20220221BHEP

Ipc: A61K 47/64 20170101ALI20220221BHEP

Ipc: A61K 41/00 20060101AFI20220221BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240201